endometrial neoplasms/povraćanje

Veza se sprema u međuspremnik

Odaberite vrstu sortiranja

Stranica 1 iz 57 rezultatima

The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

BACKGROUND Dexamethasone is widely used for postoperative nausea and vomiting (PONV) prophylaxis. However, there are limited data on the risk of wound complications associated with single-dose dexamethasone use for this purpose. We performed this retrospective study to determine whether

Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

OBJECTIVE To assess whether antiemetic doses of dexamethasone are associated with an increased risk of cancer recurrence in women who underwent surgery for endometrial cancer. METHODS This is a retrospective study at an academic university medical center. Women who underwent surgery for endometrial

[A case of recurrent endometrial cancer successfully treated with oral administration of etoposide].

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

A 61-year-old female with recurrent endometrial cancer (serous papillary adenocarcinoma) was treated with etoposide because the pelvic tumor progressively increased in size with external beam irradiation. The etoposide (25 mg/day) was given orally for 10 days; the tumor decreased in size. And after

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

BACKGROUND Activating FGFR2 mutations are found in 10-16% of primary endometrial cancers and provide an opportunity for targeted therapy. We assessed the safety and activity of dovitinib, a potent tyrosine-kinase inhibitor of fibroblast growth factor receptors, VEGF receptors, PDGFR-β, and c-KIT, as

[Combination effect of granisetron plus corticosteroid for prevention of cisplatin-induced emesis: a cross-over study comparing methylprednisolone and dexamethasone].

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Granisetron (G) is an effective antiemetic drug that is used to prevent cisplatin-induced emesis, although it is less effective for delayed emesis. To enhance the antiemetic effects of granisetron, corticosteroid analogues such as methylprednisolone (M) and dexamethasone (D) were employed in a study

A retrospective evaluation of the perioperative drug use and comparison of its cost in robotic vs open surgery for endometrial cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

To compare the usage and cost of analgesics (opioid and non-opioids), antiemetics, and IV fluids and its associated costs in robotic vs open staging surgery for endometrial cancer (EC). This retrospective study was performed at a single academic institution from January 2014 to June 2017 in the

Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

To compare the Ki-67 index of endometrial cancer cells before and after treatment between the metformin and placebo group in women with endometrial cancer (EC).This study was a randomized, double-blind, placebo-controlled trial conducting in non-diabetic

Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

OBJECTIVE To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen. METHODS Forty consecutive patients with stage III or IV epithelial ovarian cancer or advanced or

Carboplatin therapy in advanced endometrial cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

A phase II study of the effectiveness and toxicity of carboplatin in the treatment of metastatic or locally advanced endometrial cancer was carried out by the Southwest Oncology Group. Thirty-two patients were registered in the study and 23 were fully evaluable for response and toxicity. Carboplatin

Cisplatin chemotherapy for disseminated endometrial cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Twenty-six women with advanced or recurrent endometrial cancer were treated with cisplatin at a dose of 50, 70, or 100 mg/m2 every 4 weeks. An objective response was obtained in 11 of 26 patients (42%), with 10 partial responses and 1 complete response. The median duration of remission was 5 months,

Long-term quality of life after comprehensive surgical staging of high-risk endometrial cancer - results from the RASHEC trial.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

OBJECTIVE The health-related quality of life (HRQoL) outcomes after comprehensive surgical staging including infrarenal paraaortic lymphadenectomy in women with high-risk endometrial cancer (EC) are unknown. Our aim was to investigate the long-term HRQoL between robot-assisted laparoscopic surgery

Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: a retrospective clinical study.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

The combination of cisplatin (50 mg/m2), epirubicin (60 mg/m2), and cyclophosphamide (600 mg/m2) (PEC regimen) was given every 4 weeks to 19 patients with advanced (n.2) or recurrent (n.17) endometrial cancer. The median number of cycles delivered to each patient was 5 (range, 2-8). All patients

Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

OBJECTIVE The optimal chemotherapy regimen for patients with endometrial cancer has not been established. We assessed the feasibility of paclitaxel plus carboplatin (TC) for postoperative chemotherapy in patients with endometrial cancer. METHODS Patients with newly diagnosed endometrial cancer

Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

OBJECTIVE The purpose of this study was to determine the activity and toxicity of carboplatin and paclitaxel (taxol) in the treatment of advanced or recurrent endometrial cancer. METHODS This was a retrospective review of 18 consecutive patients with advanced (stage 4) or recurrent endometrial

[Combination chemotherapy using cyclophosphamide, adriamycin, and cisplatin in recurrent or advanced endometrial cancer--a preliminary report].

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Four patients with recurrent or advanced endometrial cancer have undergone combination chemotherapy with Cyclophosphamide, Adriamycin and Cisplatin (CAP). All drugs were administered by I.V. on day 1 in the following doses: Cyclophosphamide 500 mg/m2, Adriamycin 50 mg/m2 and Cisplatin 50 mg/m2. The

Prethodni
1
2
3
4
Sljedeći

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta znanošću

Radi na 55 jezika
Biljni lijekovi potpomognuti znanošću
Prepoznavanje bilja slikom
Interaktivna GPS karta - označite bilje na mjestu (uskoro)
Pročitajte znanstvene publikacije povezane s vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima